IL100858A - 2-Amino-1,2,3,4-Tetrahydronaphthalene and 3-Aminochromes are converted into a pharmaceutical composition ring containing them and a process for their preparation - Google Patents

2-Amino-1,2,3,4-Tetrahydronaphthalene and 3-Aminochromes are converted into a pharmaceutical composition ring containing them and a process for their preparation

Info

Publication number
IL100858A
IL100858A IL10085892A IL10085892A IL100858A IL 100858 A IL100858 A IL 100858A IL 10085892 A IL10085892 A IL 10085892A IL 10085892 A IL10085892 A IL 10085892A IL 100858 A IL100858 A IL 100858A
Authority
IL
Israel
Prior art keywords
compound
formula
alkyl
mixture
hydrogen
Prior art date
Application number
IL10085892A
Other languages
English (en)
Hebrew (he)
Other versions
IL100858A0 (en
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Priority to IL11476092A priority Critical patent/IL114760A/xx
Publication of IL100858A0 publication Critical patent/IL100858A0/xx
Publication of IL100858A publication Critical patent/IL100858A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Lubricants (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL10085892A 1991-02-08 1992-02-03 2-Amino-1,2,3,4-Tetrahydronaphthalene and 3-Aminochromes are converted into a pharmaceutical composition ring containing them and a process for their preparation IL100858A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL11476092A IL114760A (en) 1991-02-08 1992-02-03 Ring-substituted-2-amino-1,2,3,4-tetrahydronaphthalenes and 3-aminochromanes intermediates thereto

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65358391A 1991-02-08 1991-02-08

Publications (2)

Publication Number Publication Date
IL100858A0 IL100858A0 (en) 1992-11-15
IL100858A true IL100858A (en) 1996-03-31

Family

ID=24621480

Family Applications (3)

Application Number Title Priority Date Filing Date
IL10085892A IL100858A (en) 1991-02-08 1992-02-03 2-Amino-1,2,3,4-Tetrahydronaphthalene and 3-Aminochromes are converted into a pharmaceutical composition ring containing them and a process for their preparation
IL11476092A IL114760A (en) 1991-02-08 1992-02-03 Ring-substituted-2-amino-1,2,3,4-tetrahydronaphthalenes and 3-aminochromanes intermediates thereto
IL11476095A IL114760A0 (en) 1991-02-08 1995-07-27 Division from 100858 Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes and 3-aminochromanes and intermediates thereto

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL11476092A IL114760A (en) 1991-02-08 1992-02-03 Ring-substituted-2-amino-1,2,3,4-tetrahydronaphthalenes and 3-aminochromanes intermediates thereto
IL11476095A IL114760A0 (en) 1991-02-08 1995-07-27 Division from 100858 Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes and 3-aminochromanes and intermediates thereto

Country Status (26)

Country Link
US (2) US5426226A (zh)
EP (2) EP0498590B1 (zh)
JP (1) JP3283892B2 (zh)
KR (1) KR100219995B1 (zh)
CN (2) CN1036392C (zh)
AT (2) ATE197145T1 (zh)
AU (2) AU653197B2 (zh)
BR (1) BR9200426A (zh)
CA (1) CA2060815C (zh)
CZ (1) CZ288067B6 (zh)
DE (2) DE69231538T2 (zh)
DK (2) DK0712837T3 (zh)
ES (2) ES2153071T3 (zh)
FI (1) FI920526A (zh)
GR (2) GR3023601T3 (zh)
HU (3) HU225163B1 (zh)
IE (1) IE920417A1 (zh)
IL (3) IL100858A (zh)
MX (1) MX9200505A (zh)
MY (1) MY116454A (zh)
NO (1) NO301825B1 (zh)
NZ (2) NZ241495A (zh)
PT (1) PT712837E (zh)
RU (2) RU2057751C1 (zh)
YU (1) YU48927B (zh)
ZA (1) ZA92767B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE149480T1 (de) * 1990-08-15 1997-03-15 Lilly Co Eli Ring-substituierte 2-amino-1,2,3,4-tetra- hydronaphthaline, 3-aminochromane und 3- aminothiochromane
DK0712837T3 (da) * 1991-02-08 2000-11-20 Lilly Co Eli Ringsubstituerede 2-amino-1,2,3,4-tetrahydronaphtalener og 3-aminochromaner
US5434174A (en) * 1992-07-17 1995-07-18 Eli Lilly And Company Isoxazole derivatives for the treatment of irritable bowel syndrome
WO1994022495A1 (en) * 1993-03-31 1994-10-13 The Trustees Of The University Of Pennsylvania Dopamine d-3 and serotonin (5-ht1a) receptor ligands and imaging agents
IL110857A0 (en) * 1993-09-09 1994-11-28 Lilly Co Eli Cessation of tobacco use
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
US6355674B1 (en) 1997-04-30 2002-03-12 Eli Lilly And Company Aminotetralins as 5-HT1D α Agonists
AU7163598A (en) * 1997-04-30 1998-11-24 Eli Lilly And Company Aminotetralins as 5-ht1dalpha agonists
CN1256085C (zh) 1997-07-01 2006-05-17 美国辉瑞有限公司 舍曲林盐和舍曲林的缓释剂型
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
KR20010079778A (ko) * 1998-09-09 2001-08-22 이시하라 겐조 제초제로 유용한 융합-벤젠 유도체
FR2792529B1 (fr) * 1999-04-26 2001-09-28 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
US6792563B1 (en) * 2000-04-28 2004-09-14 Intel Corporation Method and apparatus for bus activity tracking
WO2003068227A1 (en) * 2002-02-13 2003-08-21 Pharmagene Laboratories Limited 5-ht2b receptor antagonists
SE0301795D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use I
SE0301794D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use III
SE0301798D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use IV
SE0301796D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use II

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ192641A (en) * 1979-01-26 1984-10-19 Hoffmann La Roche Substituted acetophenones and pharmaceutical compositions
SE8004002L (sv) * 1980-05-29 1981-11-30 Arvidsson Folke Lars Erik Terapeutiskt anvendbara tetralinderivat
US4801605A (en) * 1986-08-29 1989-01-31 Ciba-Geigy Corporation 3-amino-dihydro-[1]-benzopyrans and benzothiopyrans
SE8605504D0 (sv) * 1986-12-19 1986-12-19 Astra Laekemedel Ab Novel chroman derivatives
DE3719924A1 (de) * 1986-12-22 1988-06-30 Bayer Ag 8-substituierte 2-aminotetraline
US5214156A (en) * 1988-03-25 1993-05-25 The Upjohn Company Therapeutically useful tetralin derivatives
CA1335591C (en) * 1988-05-23 1995-05-16 James Arthur Nixon Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
CA1335106C (en) * 1989-02-27 1995-04-04 John Mehnert Schaus Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
FR2647365B1 (fr) * 1989-05-24 1991-08-30 Inst Francais Du Petrole Catalyseur multifonctionnel pour le traitement des gaz d'echappement des moteurs a combustion interne, contenant de l'uranium, au moins un promoteur de l'uranium et au moins un metal precieux et sa preparation
SE8901889D0 (sv) * 1989-05-26 1989-05-26 Astra Ab Novel 8-substituted-2-aminotetralines
ATE172712T1 (de) * 1989-05-31 1998-11-15 Upjohn Co Zns-wirksame 8-heterocyclyl-2-aminotetralin derivate
DE3919624A1 (de) * 1989-06-15 1990-12-20 Boehringer Ingelheim Kg Neue 2,5-diaminotetraline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
AU631017B2 (en) * 1989-10-23 1992-11-12 Sumitomo Chemical Company, Limited 5-substituted-2,4-diphenylpyrimidine derivatives, their production and use
SE8904361D0 (sv) * 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
US5420151A (en) * 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
ATE149480T1 (de) * 1990-08-15 1997-03-15 Lilly Co Eli Ring-substituierte 2-amino-1,2,3,4-tetra- hydronaphthaline, 3-aminochromane und 3- aminothiochromane
DK0712837T3 (da) * 1991-02-08 2000-11-20 Lilly Co Eli Ringsubstituerede 2-amino-1,2,3,4-tetrahydronaphtalener og 3-aminochromaner

Also Published As

Publication number Publication date
HUT72659A (en) 1996-05-28
IL100858A0 (en) 1992-11-15
AU664520B2 (en) 1995-11-16
AU1077592A (en) 1992-08-13
FI920526A (fi) 1992-08-09
MY116454A (en) 2004-02-28
ZA92767B (en) 1993-08-03
CA2060815C (en) 2002-05-14
DE69231538D1 (de) 2000-11-30
NO920489L (no) 1992-08-10
US5571942A (en) 1996-11-05
EP0498590B1 (en) 1997-04-09
JP3283892B2 (ja) 2002-05-20
CZ288067B6 (cs) 2001-04-11
CZ33292A3 (en) 1993-03-17
GR3023601T3 (en) 1997-08-29
RU2105756C1 (ru) 1998-02-27
NO920489D0 (no) 1992-02-06
KR100219995B1 (ko) 1999-09-01
RU94044322A (ru) 1996-10-10
AU653197B2 (en) 1994-09-22
CN1140167A (zh) 1997-01-15
YU48927B (sh) 2002-12-10
IL114760A0 (en) 1995-11-27
BR9200426A (pt) 1992-10-13
CN1052218C (zh) 2000-05-10
YU12992A (sh) 1995-01-31
HU225163B1 (en) 2006-07-28
IE920417A1 (en) 1992-08-12
KR920016454A (ko) 1992-09-24
DK0712837T3 (da) 2000-11-20
ATE197145T1 (de) 2000-11-15
HU9200396D0 (en) 1992-04-28
EP0712837A3 (en) 1997-05-21
DK0498590T3 (da) 1997-05-05
ES2102456T3 (es) 1997-08-01
HU221184B1 (en) 2002-08-28
ATE151419T1 (de) 1997-04-15
ES2153071T3 (es) 2001-02-16
JPH04327579A (ja) 1992-11-17
NO301825B1 (no) 1997-12-15
PT712837E (pt) 2001-03-30
NZ264302A (en) 1995-04-27
HUT62569A (en) 1993-05-28
DE69218813D1 (de) 1997-05-15
EP0498590A1 (en) 1992-08-12
CA2060815A1 (en) 1992-08-09
NZ241495A (en) 1994-10-26
GR3035190T3 (en) 2001-04-30
IL114760A (en) 1997-11-20
HU211848A9 (en) 1995-12-28
FI920526A0 (fi) 1992-02-07
EP0712837B1 (en) 2000-10-25
RU2057751C1 (ru) 1996-04-10
MX9200505A (es) 1992-08-01
DE69231538T2 (de) 2001-06-07
IE970857A1 (en) 2000-02-23
CN1063870A (zh) 1992-08-26
HU9500495D0 (en) 1995-04-28
AU8168794A (en) 1995-02-23
DE69218813T2 (de) 1997-08-14
CN1036392C (zh) 1997-11-12
EP0712837A2 (en) 1996-05-22
US5426226A (en) 1995-06-20

Similar Documents

Publication Publication Date Title
IL100858A (en) 2-Amino-1,2,3,4-Tetrahydronaphthalene and 3-Aminochromes are converted into a pharmaceutical composition ring containing them and a process for their preparation
AU728329B2 (en) New substituted biphenyl or phenylpyridine compounds, a process for their preparation and pharmaceutical compositions containing them
EA004306B1 (ru) Нестероидные (гетеро)циклически замещенные ациланилиды, обладающие смешанным гестагенным и андрогенным действием
JP2001521529A (ja) 置換へテロ芳香環5−ht▲下1f▼アゴニスト
HU217590B (hu) Eljárás 6-os helyen heterociklusos csoporttal helyettesített 4-amino-1,3,4,5-tetrahidro-benz[c,d]indolok és a vegyületeket tartalmazó gyógyszerkészítmények előállítására
CZ281137B6 (cs) V jádru substituovaný 2-amino-1,2,3,4-tetrahydronaftalen-3-aminochroman a 3-aminothiochroman, způsob jejich přípravy a farmaceutické prostředky je obsahující
CZ137193A3 (en) Isoxazole derivative for treating intestine irritation syndrome and pharmaceutical preparation in which it is comprised
RU2093507C1 (ru) 8-замещенные-2-аминотетралиновые производные и способы из получения
JPH02268151A (ja) 環置換された2―アミノ―1,2,3,4―テトラヒドロナフタレンおよび3―アミノクロマン類
RU2062775C1 (ru) 6-гетероциклическизамещенные 4-амино-1,2,2а,3,4,5-гексагидробенз-(cd)-индолы или их фармацевтически приемлемые соли и способы их получения
JPH06211655A (ja) 乗物酔いおよび嘔吐症の処置用6−ヘテロ環−4−アミノ−1,3,4,5−テトラヒドロベンズ[cd]インドール類
US6166020A (en) Aryl and heteroaryl alkoxynaphthalene derivatives
US5750524A (en) Remedy for hyperlipidemia
JP2004531526A (ja) 5員複素間誘導体、その製造法及びその医薬としての使用
AU2004312284B2 (en) Non-nucleotide reverse transcriptase inhibitors
IE19970857A1 (en) Ring-substituted 2-amino-1, 2, 3, 4-tetra-hydronaphthalenes and 3-aminochromanes
JPH06211654A (ja) 乗物酔いおよび嘔吐処置用6−ヘテロ環−4−アミノ−1,2,2a,3,4,5−ヘキサヒドロベンズ[cd]インドール類
IE83295B1 (en) Ring-substituted 2-amino-1, 2, 3, 4-tetra-hydronaphthalenes and 3-aminochromanes

Legal Events

Date Code Title Description
FF Patent granted
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees